The ratio of non-hyperkeratotic and hyperkeratotic actinic keratosis in a high-risk non-melanoma skin cancer cohort in Queensland

2014 ◽  
Vol 30 (3) ◽  
pp. 473-474 ◽  
Author(s):  
J. M. Tan ◽  
S. Sinnya ◽  
H. Peter Soyer
Keyword(s):  
High Risk ◽  
Skin Cancer ◽  
Actinic Keratosis ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

scholarly journals Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series of 10 Cases

2017 ◽  
Vol 9 (3) ◽  
pp. 211-216 ◽  
Author(s):  
Virginia Garofalo ◽  
Alessandra Ventura ◽  
Sara Mazzilli ◽  
Laura Diluvio ◽  
Luca Bianchi ◽  
...  
Keyword(s):  
High Risk ◽  
Skin Cancer ◽  
Cell Carcinoma ◽  
Medical Device ◽  
Actinic Keratosis ◽  
Organ Transplant ◽  
Cyclooxygenase Inhibitors ◽  
Organ Transplant Recipient ◽  
Skin Cancers ◽  
Melanoma Skin

Organ transplant recipient (OTR) subjects are at high risk of skin cancer such as squamous cell carcinoma and basal cell carcinoma. Actinic keratosis (AK) is considered the precursor of these non-melanoma skin cancers. Sun protection is mandatory in subjects with AK and this preventive strategy is very important in OTR. Treatment of the field of cancerization is also crucial to reduce the risk of recurrence of skin lesions in AK and non-melanoma skin cancer patients. Activation of cyclooxygenase 1 and 2 enzymes plays an important role in the pathogenesis of skin cancers. Topical application of cyclooxygenase inhibitors such as diclofenac and, more recently, piroxicam has shown to reduce AK lesions in immunocompetent subjects. A medical device containing piroxicam and SPF 50+ sunscreen filters (P+SS) has been demonstrated to be effective in reducing AK lesions and improving the field of cancerization. We report the effect of P+SS, applied for 16 weeks, in a case series of 10 OTR subjects with multiple AK lesions. P+SS treatment was associated with a relevant AK lesion reduction (>75%) in 7 patients (with a complete clearance in 3 subjects) with an improvement in the field of cancerization. This medical device could be considered a promising long-term curative and preventive treatment in OTR patients at high risk of non-melanoma skin cancers.

Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer

2014 ◽  
Vol 24 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Gunnar Grue-Sørensen ◽  
Xifu Liang ◽  
Kristoffer Månsson ◽  
Per Vedsø ◽  
Morten Dahl Sørensen ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Actinic Keratosis ◽  
Biological Evaluation ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer

2013 ◽  
Vol 23 (20) ◽  
pp. 5624-5629 ◽  
Author(s):  
Xifu Liang ◽  
Gunnar Grue-Sørensen ◽  
Kristoffer Månsson ◽  
Per Vedsø ◽  
Anke Soor ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Actinic Keratosis ◽  
Biological Evaluation ◽  
Ingenol Mebutate ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin
Sign in / Sign up

Export Citation Format

Share Document